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(2 vs. 4 days); risk of re-intervention at 5 years (7% vs. 15%); complexity of follow-up 
(with vs. without CT examination); risk of major complications (2% vs. 5%); addi-
tional cost of intervention (a0 vs. a2000). The respondents were asked to choose the 
preferred described treatment among the options presented. The relative importance 
(RI) of each characteristic included in the scenarios was estimated by adopting a con-
ditional logistic regression model. RESULTS: 157 patients, 102 caregivers and 30 
surgeons from 9 Italian hospitals participated. Patients’ mean age  72.6 (49–88) years, 
male  91.7%. Fifty-four percent were expecting to undergo repair intervention, the 
others already received endovascular (43.4%) or surgical (50.6%) treatment. Overall, 
major complication risk was considered the most important characteristic (RI  
42.3%), then cost (RI  24.5%), risk of re-intervention at 5 years (19.2%), recovery 
time (RI  9.0%), complexity of follow-up (RI  8.7%). Type of anaesthesia was 
considered the least important characteristic (RI  3.6%). Subgroup analyses showed 
some different preferences: only patients considered signiﬁcant the recovery time and 
only physicians assigned signiﬁcant importance to the complexity of follow-up. CON-
CLUSIONS: While some characteristics (e.g. major complication rate) obtained the 
anticipated relative importance, other attributes (type of anaesthesia, follow-up, cost) 
showed different values than expected. Knowledge of preferences for AAA treatment 
options that can inﬂuence decision making and/or beneﬁts can help to optimize treat-
ment strategies.
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OBJECTIVES: Venous thromboembolism (VTE) is a common disorder. In Germany 
the current standard of thromboprophylaxis is subcutaneously administered low-
molecular-weight heparin. Meanwhile, orally administered alternatives are available. 
Primary objective of the study was to investigate patient burden and preferences and 
time consumption in the use of thromboprophylaxis. METHODS: The open, prospec-
tive observational study, enrolling adult patients after elective total hip (THR) and 
knee (TKR) replacement, was carried out from October 2008 until March 2009. Time 
was recorded for individual steps in the administration process ranging from syringe 
preparation, syringe administration, tablet preparation to tablet administration. Fur-
thermore patient-satisfaction, burden of daily subcutaneous administration and daily 
intake of tablets were recorded. Preference of patient for an oral or subcutaneous 
administration was inquired. RESULTS: The investigations were conducted in 6 
general hospitals and 6 rehab centers. 178 patients answered the questionnaire (41.4% 
TKR, 58,6% THR). The patients were on average 68.38 years old (SD: 9.82; TKR: 
69.69 years, SD: 7.31; THR: 67.22 years, SD:11.29), 73,6% (TKR: 81,9%, THR: 
67.6%) regularly (longer than 6 months) take tabletts. Most of the patients (71.9%, 
TKR: 72.2 %; THR: 70.59%) would prefer a tablet. Total time required for syringe 
preparation and administration was 73.11 sec (SD: 34.06 sec) compared to 26.98 sec 
(SD: 19.41 sec) for tablet. Most time-consuming process was syringe administration 
(50.27 sec, SD: 31.22 sec), followed by syringe preparation (22.84 sec, SD: 13.61 sec), 
tablet administration (18.17 sec, SD: 18.52) and preparation of tablet (8.82, SD: 5.79). 
CONCLUSIONS: Occasionally, only little data were available for patient preferences 
and burden of subcutaneous administration compared to oral medication. The major-
ity of patients would prefer the intake of a tablet. Also it was shown that in daily 
hospital routine a reduction of total time for thromboprophylaxis by using a tablet 
instead of a syringe is possible.
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OBJECTIVES: To assess preferences for and valuation of attributes of anticoagulation 
therapy (ACT) modelled on the oral direct thrombin inhibitor dabigatran etexilate 
(DAB) relative to warfarin in UK atrial ﬁbrillation (AF) patients receiving warfarin. 
METHODS: The pilot study employed discrete choice analysis to derive preference 
and willingness-to-pay (WTP) estimates, based on treatment attributes that distinguish 
DAB from warfarin. Attributes included: dose frequency; anticoagulation monitoring; 
diet, alcohol and certain analgesic restrictions; use of different tablet strengths to make 
up correct daily dose. Stroke risk on therapy was assumed not to differ between DAB 
and warfarin. AF patients (n  32) currently receiving warfarin (mean time on therapy 
 45.0mo) were asked to make pair-wise medication choices between a ﬁxed scenario 
representing warfarin and 12 alternatives, including a scenario modelled on DAB, ﬁrst 
without and then with consideration of cost. Comparisons were designed to elicit 
trade-offs to determine preferences. Statistical analysis (logistic regression models) of 
preference without cost consideration excluded any irrational traders. Analysis of 
WTP excluded both irrational and non-traders. RESULTS: Rational respondents (n  
30) showed no signiﬁcant preference between an ACT modelled on DAB and warfarin 
(OR  0.95 [95%CI: 0.28–3.25]). However, respondents signiﬁcantly preferred a 
medication that avoided different tablet strengths (p  0.011), i.e., an attribute in 
favour of DAB. Rational traders (n  19) were willing to pay an incremental £26.60 
[95%CI: 66.00, 128.00] per month for DAB. A demand curve indicated that 72% 
and 50% would choose DAB over warfarin at an incremental cost of zero and £40 
respectively. CONCLUSIONS: AF respondents receiving warfarin showed indifference 
between an ACT modelled on DAB and warfarin, perhaps reﬂecting respondents’ 
familiarity and success with, and acceptance of the limitations of warfarin. Among 
respondents who were willing to trade, WTP for DAB was not signiﬁcant. This pilot 
was limited by the high proportion (41%) of non-traders in the study.
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OBJECTIVES: To assess preferences for and valuation of attributes of an anticoagula-
tion therapy (ACT) modelled on the oral direct thrombin inhibitor dabigatran etexilate 
(DAB) relative to warfarin in UK atrial ﬁbrillation (AF) patients, naïve to warfarin. 
METHODS: The pilot study employed discrete choice analysis to derive willingness-
to-pay (WTP) estimates as a measure of preference, based on treatment attributes that 
distinguish DAB from warfarin. Attributes included: dose frequency; anticoagulation 
monitoring; diet, alcohol and certain analgesic restrictions; use of different tablet 
strengths to make up correct daily dose. Stroke risk was assumed not to differ between 
DAB and warfarin. Warfarin-naïve AF patients (n  32) made pair-wise medication 
choices between a ﬁxed scenario representing warfarin and 12 alternatives, including 
a scenario modelled on DAB, ﬁrst without and then with consideration of cost. Com-
parisons were designed to elicit trade-offs to determine preferences. Statistical analysis 
(logistic regression models) of preference without cost consideration excluded any 
irrational traders. Analysis of WTP excluded both irrational and non-traders. 
RESULTS: When cost was not considered, rational respondents (n  30) showed sig-
niﬁcant preference for an ACT modelled on DAB over warfarin (OR  3.65 [95%CI: 
1.09–12.22]). Avoiding different tablet strengths was a signiﬁcant choice driver (p  
0.006). Rational traders (n  18) were willing to pay an incremental £73.90 [95%CI: 
17.30–141.40] per month for DAB. A demand curve indicated that 88.4% would 
choose DAB over warfarin at zero incremental cost and 50% would choose DAB at 
an incremental of £49. In these respondents, avoiding INR monitoring was a signiﬁ-
cant choice driver (p  0.039). CONCLUSIONS: Warfarin-naïve AF patients showed 
a strong preference for an ACT modelled on DAB over warfarin. Among respondents 
who were willing to trade, there was a signiﬁcant WTP for the convenience of DAB. 
This pilot study of WTP was limited by the high proportion (37.5%) of respondents 
who were unwilling to trade.
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OBJECTIVES: To explore upper gastrointestinal (GI) symptoms in patients with 
 cardiovascular (CV) risk who require low-dose acetylsalicylic acid (ASA; aspirin) 
therapy, and patients’ evaluation of GI symptoms. METHODS: This multicentre, 
observational study (ClinicalTrials.gov identiﬁer: NCT00681759; AstraZeneca study 
code: D961FC00004), conducted at 77 centres in USA, Canada and France, included 
patients q18 years at risk of or with CV disease, prescribed daily low-dose ASA (75–
325 mg) within the past 5 years or who were about to begin low-dose ASA therapy. 
Patients were surveyed to collect 12-months retrospective data on: GI symptoms, 
low-dose ASA use, and the impact of dyspeptic symptoms on adherence to low-dose 
ASA and other CV medications. Patients completed the 12-item Short-Form Health 
Survey (SF-12), the Hospital Anxiety and Depression Scale (HADS) and the 8-item 
Morisky Medication Adherence Scale (MMAS-8). RESULTS: In total, 1770 patients 
(mean age 57 years; 54% women) were assessed; 81.0% were aged 70 years. Most 
patients (71%) needed low-dose ASA for secondary or high-risk primary CV preven-
tion; 29% of patients were low-dose ASA-naïve. Among patients with GI symptoms 
(n  935) in the past year, 547 (58.5%) experienced GI symptoms within 14 days 
prior to survey completion. Of these, 380 (69.5%) attributed sleeping difﬁculties 
during the previous week to their GI symptoms; one quarter described sleeping 
 difﬁculties as occurring often or daily. A total of 366 patients (66.9%) had dyspeptic 
symptoms in the past 14 days. Patients who experienced dyspeptic symptoms had 
signiﬁcantly worse SF-12 domain scores (all p  0.01) and HADS anxiety and depres-
sion domain scores (p  0.01) than those without dyspeptic symptoms. Patients with 
dyspeptic symptoms taking CV medications, had signiﬁcantly lower CV medication 
compliance scores, than patients without dyspeptic symptoms (p  0.03). CONCLU-
SIONS: Among patients requiring low-dose ASA for cardioprotection, those who 
experience dyspeptic symptoms report worse health scores, increased anxiety and 
depression levels, and poorer compliance with CV medications.
